The funding was led by Fountain Healthcare Partners, Forbion, and Andera Partners, with support from existing investors V-Bio Ventures, BGV, PMV, VIB, HTGF, and GFF.

In addition, Bernard Coulie, CEO of Pliant Therapeutics, joined Dualyx as independent chairman with immediate effect. Ena Prosser, Juliette Audet, and Aneta Sottil will join Dualyx's board as non-executive directors.

The Ghent, Belgium-based firm said that the funds will be used to progress its principal regulatory T cell (Treg) therapy for a range of autoimmune diseases, the DT-001 program, to its early clinical proof-of-concept phase, along with advancing other Treg therapies in its pipeline.

DT-001 targets the TNF receptor 2 (TNFR2), considered a master control switch in immune modulation. Pre-clinical research with DT-001 has yielded promising results, and investigational new drug (IND)-enabling studies have begun.

"Attracting the expertise and support of top-tier investors to Dualyx highlights the potential of the work to date in our DT-001 program and more importantly, completes our high-quality international investor base," Wouter Verhoeven, CEO of Dualyx, said in a statement.

Study uncovers novel biomarker and potentially improved therapy for multiple sclerosis
Multiple sclerosis (MS) and related neurodegenerative disorders, including Alzheimer’s and Huntington’s disease, affect about 2.8 million people worldwide....

RNA biomarkers may help confirm heart disease, study finds
An analysis of blood RNA from patients with angiographically confirmed coronary artery disease has shown how RNA biomarkers may be used to confirm heart...

Analysis of T-cell receptors sheds light on cause of autoimmune diseases
An analysis of T-cell receptors by researchers at the Washington University School of Medicine, and colleagues at Stanford University and Oxford University,...

Rogue killer T cells contribute to autoimmunity: study
Scientists from the Garvan Institute of Medical Research have found new insight into the role that killer T cells play in leukemia and autoimmune disease....

Metabolic control of Tregs is critical for immune tolerance
A new study identifies how metabolism exerts control over regulatory T (Treg) cells, which play a key role in the recognition of foreign and self-produced...